Table 1.
Baseline patient characteristics and discharge diagnoses
| Males (n=10, 36%) | Females (n=18, 64%) | All patients (n=28) | |
|---|---|---|---|
| Age at admission (years) | 16 ± 1.5 | 15.5 ± 2.3 | 15.7 ± 2 |
| Mean ± SD (min–max) | (13.3–17.7) | (10.7–18.9) | (10.7–13.9) |
| Age at clozapine start (years) | 16.1 ± 1.5 | 15.7 ± 2.3 | 15.8 ± 2 |
| Mean ± SD (min–max) | (13.6–17.9) | (11.1–19.3) | (11.1–19.3) |
| Weight (kg) at admission, Mean ± SD | 84.3 ± 22.8 | 49.1 ± 11.4 | 61.7 ± 23.5 |
| n = 10 | n = 18 | n = 28 | |
|
|
|||
| Race/Ethnicity | |||
| White/Caucasian | 3 | 5 | 8 |
| Chinese | 3 | 3 | 6 |
| Filipino | - | 3 | 3 |
| Southeast Asian | 3 | - | 3 |
| Aboriginal | - | 2 | 2 |
| Black/African | - | 2 | 2 |
| South Asian | 1 | 1 | 2 |
| Latin American | - | 1 | 1 |
| Japanese | - | 1 | 1 |
| n (%) | n (%) | n (%) | |
|
|
|||
| History of cannabis use | 5 (50) | 5 (27.7) | 10 (35.7) |
| Tobacco smoking at clozapine initiation | 1 (3.6) | 1 (3.6) | 2 (7.1) |
| Primary psychotic illness | 10 (100) | 15 (83.3) | 25 (89.3) |
| Affective illness present | 4 (40) | 9 (50) | 13 (46.4) |
| First mental health presentation | 2 (20) | 5 (27.8) | 7 (25) |
| Antipsychotic drug trials prior to clozapine initiation, mean ± SD | 2.8 ± 1.2 | 3.0 ± 1.5 | 2.9 ± 1.3 |
| Discharge diagnoses (per treating psychiatrist / non-retrospective): | |||
| Schizophreniform | 1 (10) | 2 (11.1) | 3 (10.7) |
| Schizophrenia | 5 (50) | 6 (33.3) | 11 (39.3) |
| Schizoaffective | 4 (40) | 7 (38.9) | 11 (39.3) |
| Bipolar disorder | 0 (0) | 2 (11.1) | 2 (7.1) |
| Non-psychotic non-bipolar illness | 0 (0) | 1 (5.6) | 1 (3.6) |